Genetech's upcoming plans with T-DM1
 

http://www.immunogen.com/wt/page/trastuzumab_DM1

Genentech has disclosed the following in terms of the T-DM1 development plans:

• They plan to initiate a Phase III trial evaluating T-DM1 as a second-line treatment for HER2-positive metastatic breast cancer (MBC) in the first half of 2009. We have disclosed that the initiation of Phase III testing with T-DM1 triggers a milestone payment to ImmunoGen.
• They have initiated a Phase II trial in August 2008 that evaluates T-DM1 as a third-line treatment for this cancer, another potential route to market for T-DM1.
• They have initiated a Phase II trial comparing T-DM1, given as a single agent, to Herceptin (trastuzumab) plus Taxotere (docetaxel) as a first-line treatment for this cancer; and
• They plan to start a Phase Ib trial in the first half of 2009 to evaluate T-DM1 given in combination with their pertuzumab compound (this one excites me for Caryn who responded VERY well to the DM1 but got thrown off because her body didn't handle the higher dose well)

Eric, I like the sound of that pertuzumab trial as well - blocking more pathways is definitely a good thing, and if they can do so with a lower dose of the DM1...that might also be a good thing!

This really does sound terrific!!!

Very interesting and sounds promising for a lot of people.

Genentech's T-DM1 vs Tykerb/Xeloda phaseIII trial is now accepting candidates.
http://www.clinicaltrials.gov/ct2/sh...dm1+III&rank=1